Notice Number: NOT-NS-18-019
Release Date: November 27, 2017
PAR-19-039 - Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01 Clinical Trial Not Allowed)
PAR-19-040 -Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)
PAR-20-253 - Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects (R21 Clinical Trial Not Allowed)
PAR-20-316 - NIH Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 - Clinical Trial Optional)
The purpose of this notice is to highlight the NIH/NINDS Countermeasures Against Chemical Threats (CounterACT) program's interest in developing safe and effective therapeutics that would prevent morbidity and mortality following exposure to the opioids fentanyl, carfentanil, acetylfentanyl, alfentanil, and/or diacetylmorphine (heroin). The program concentrates on developing therapeutics to treat and/or prevent injuries and deaths that may result from exposure to chemical threats in a variety of scenarios. Applications are being accepted under three specific Funding Opportuntiy Announcements (FOAs) issued by the NIH CounterACT program (PAR-15-315, PAR-16-330, and PAR-16-331). To be considered appropriate to these FOAs, applications must follow the instructions and general descriptions found in these FOAs as well as the following requirements related to the specialized mission of the NIH CounterACT program.
Research supported by these FOAs must be relevant to chemical emergencies where the general civilian population might be exposed to opioids. The research might include industrial accidents, natural disasters causing casualties, or deliberate attacks again civilians. Some examples of research that could be supported include, but are not limited to, the following:
The NIH CounterACT program will support exploratory and developmental research (PAR-15-315) as well as the identification (PAR-16-330) and optimization (PAR-16-331) of therapeutic lead compounds. Potential applicants should see the descriptions of scientific scope found in these FOAs.
Applicants are strongly urged to contact NIH representatives listed below prior to submission.
Please direct all general NIH CounterACT inquiries to:
David A. Jett, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Please direct specific opioid research inquiries:
Kiran Vemuri, Ph.D.
National Institute on Drug Abuse (NIDA) Telephone:301-402-3396